SCHEMBL19030740

SCHEMBL19030740

Fc1ccc2c(c1)OC1(C2)CN(CC(F)F)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 4/20 0.43
▸ HTR2A P28223 4/20 0.43
▸ HTR2C P28335 4/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ CCR1 P32246 11/20 0.34
▸ KCNH2 Q12809 4/20 0.34
▸ RIPK1 Q13546 1/20 0.33
▸ CHRNA7 P36544 1/20 0.32
▸ HDAC3 O15379 1/20 0.32
▸ HDAC4 P56524 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC7 Q8WUI4 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ HDAC10 Q969S8 1/20 0.32
▸ HDAC11 Q96DB2 1/20 0.32
▸ HDAC8 Q9BY41 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ HDAC9 Q9UKV0 1/20 0.32
▸ HDAC5 Q9UQL6 1/20 0.32
▸ EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935086 0.79 DRD2 (0.43) DRD2HTR2AHTR2CKCNH2CHRNA7
SCHEMBL19029958 0.79 DRD2 (0.43) DRD2HTR2AHTR2CKCNH2CHRNA7
SCHEMBL19030659 0.77 EPHX2 (0.39) DRD2HTR2AHTR2CRIPK1CHRNA7
SCHEMBL28650476 0.74 DRD2 (0.47) DRD2HTR2AHTR2CCCR1KCNH2
SCHEMBL19030453 0.73 IRAK4 (0.40) IRAK4
SCHEMBL19030580 0.72 HTR2C (0.39) DRD2HTR2AHTR2CHDAC3HDAC4
SCHEMBL19045865 0.72 IRAK4 (0.41) IRAK4CCR1KCNH2
SCHEMBL19030087 0.72 HTR2A (0.51) DRD2HTR2AHTR2CCCR1KCNH2
SCHEMBL19030067 0.71 HTR2A (0.57) DRD2HTR2AHTR2CCCR1KCNH2
SCHEMBL19030507 0.71 HTR2C (0.41) DRD2HTR2AHTR2CCCR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS GENENTECH, INC. (US) 2022-10-20 — — US disclosed
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators GENENTECH, INC. (US) 2021-04-27 — — US disclosed
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators GENENTECH, INC. (US) 2021-04-27 — — US disclosed
EP-3394066-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS H. Hoffnabb-La Roche Ag (CH) 2018-10-31 — — EP disclosed
US-20180298015-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS GENENTECH, INC. (US) 2018-10-18 — — US disclosed
WO-2017108723-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2017-06-29 — — WO disclosed
WO-2017108723-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2017-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298015-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK1, IRAK4, IRAK2 DRD2 4427/4885HTR2A 3027/4885HTR2C 2411/4885
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK1, IRAK4, IRAK2 DRD2 4590/4885HTR2A 3526/4885HTR2C 2980/4885
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators IRAK1, IRAK4, IRAK2 DRD2 4427/4885HTR2A 3027/4885HTR2C 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback